Amendment ID: S2020-41-R1

Redraft Amendment 41

Impact fees on pharmaceutical manufacturers

Messrs. Wolf and Montigny move to amend the bill by inserting the following new section:

SECTION XX:  Pharmaceutical product manufacturers and stewardship organizations, as defined in section 1 of Chapter 94G shall, in consultation with the department of public health, identify technology to quantify, sort and catalogue covered drugs, as defined in Chapter 94G. The department shall file with the clerks of the senate and house of representatives, not later than January 1, 2018, a report detailing a program that: 1) develops a reasonable price per pill for each covered drug, as defined in Chapter 94G;  2) assesses upon each pharmaceutical product manufacturer, as defined in Chapter 94G, a fee equal to the price per pill multiplied by the number of pills collected; and 3) deposits fees collected from the program into the Prescription Drug Awareness Trust Fund established by section 2J of chapter 111. The clerks shall forward the report detailing the program to the joint committee on public health and the house and senate committees on ways and means on or before January 30, 2018. The program shall be made available to the public on the general court’s website.